Optiver Holding
OCUL icon

Optiver Holding’s Ocular Therapeutix OCUL Stock Holding History

Optiver Holding’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$85 – 3004
2026
Q1 		$85 Sell
10
-563
-98% -$5.37K ﹤0.01% 2246
2025
Q4 		$6.96K Sell
573
-404
-41% -$4.91K ﹤0.01% 1236
2025
Q3 		$11.4K Buy
977
+132
+16% +$1.58K ﹤0.01% 1215
2025
Q2 		$7.84K Hold
845
– – ﹤0.01% 1073
2025
Q1 		$6.19K Hold
845
– – ﹤0.01% 1037
2024
Q4 		$7.22K Buy
845
+805
+2,013% +$7.85K ﹤0.01% 808
2024
Q3 		$348 Sell
40
-1,285
-97% -$10.6K ﹤0.01% 923
2024
Q2 		$9.06K Buy
+1,325
New +$8.18K ﹤0.01% 730

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Optiver Holding's OCUL Position: Q2 2026 in Review

Optiver Holding sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 10 shares — an estimated $85 sold.

Optiver Holding first reported a position in OCUL in Q2 2024 and held it in 8 quarters. The position peaked at $11.4K in Q3 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Optiver Holding reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
  • Optiver Holding sold 10 Ocular Therapeutix shares in Q2 2026, an estimated $85.
  • Optiver Holding first reported a position in Ocular Therapeutix in Q2 2024 and held it in 8 quarters.
  • Optiver Holding's Ocular Therapeutix position peaked at $11.4K in Q3 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.